PURPOSE: We compared the short-term risk of falls among recipients of oxybutynin or tolterodine to treat urinary incontinence. MATERIALS AND METHODS: We conducted a population based, retrospective cohort study with propensity score matching among patients 66 years old or older who commenced treatment with oxybutynin or tolterodine in Ontario, Canada. The primary outcome was a hospital visit for a fall within 90 days of drug initiation. Secondary outcomes included hospital visits for fractures, delirium or all cause mortality. RESULTS: We found no difference in the risk of falls among users of oxybutynin vs tolterodine (adjusted hazard ratio 1.04, 95% CI 0.95 to 1.14). Secondary analyses revealed no differential risk of fractures (aHR 0.96, 95% CI 0.82 to 1.13) or delirium (aHR 0.90, 95% CI 0.66 to 1.23) associated with oxybutynin. However, statistically significant increases in the risk of all cause hospitalization (aHR 1.12, 95% CI 1.07 to 1.17) and death (aHR 1.20, 95% CI 1.07 to 1.35) were seen with oxybutynin. CONCLUSIONS: Oxybutynin was not associated with a short-term increased risk of hospital visit for falls, fractures or delirium compared to tolterodine. Further research is needed to confirm whether oxybutynin is associated with an increased risk of hospitalization or death.
PURPOSE: We compared the short-term risk of falls among recipients of oxybutynin or tolterodine to treat urinary incontinence. MATERIALS AND METHODS: We conducted a population based, retrospective cohort study with propensity score matching among patients 66 years old or older who commenced treatment with oxybutynin or tolterodine in Ontario, Canada. The primary outcome was a hospital visit for a fall within 90 days of drug initiation. Secondary outcomes included hospital visits for fractures, delirium or all cause mortality. RESULTS: We found no difference in the risk of falls among users of oxybutynin vs tolterodine (adjusted hazard ratio 1.04, 95% CI 0.95 to 1.14). Secondary analyses revealed no differential risk of fractures (aHR 0.96, 95% CI 0.82 to 1.13) or delirium (aHR 0.90, 95% CI 0.66 to 1.23) associated with oxybutynin. However, statistically significant increases in the risk of all cause hospitalization (aHR 1.12, 95% CI 1.07 to 1.17) and death (aHR 1.20, 95% CI 1.07 to 1.35) were seen with oxybutynin. CONCLUSIONS:Oxybutynin was not associated with a short-term increased risk of hospital visit for falls, fractures or delirium compared to tolterodine. Further research is needed to confirm whether oxybutynin is associated with an increased risk of hospitalization or death.
Authors: Joseph T Hanlon; Xinhua Zhao; Jennifer G Naples; Sherrie L Aspinall; Subashan Perera; David A Nace; Nicholas G Castle; Susan L Greenspan; Carolyn T Thorpe Journal: J Am Geriatr Soc Date: 2017-02-02 Impact factor: 5.562
Authors: Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu Journal: Int J Geriatr Psychiatry Date: 2020-11-18 Impact factor: 3.850
Authors: Shelagh M Szabo; Katherine Gooch; Carol Schermer; David Walker; G Lozano-Ortega; Basia Rogula; Alison Deighton; Edward Vonesh; Noll Campbell Journal: BMJ Open Date: 2019-05-05 Impact factor: 2.692
Authors: Martin C S Wong; Wilson W S Tam; Harry H X Wang; Clement S K Cheung; Ellen L H Tong; Antonio C H Sek; N T Cheung; Bryan P Y Yan; C M Yu; Stephen R Leeder; Sian M Griffiths Journal: Int J Cardiol Date: 2013-07-26 Impact factor: 4.164
Authors: Mina Tadrous; Ahmad Shakeri; Cherry Chu; Jennifer Watt; Muhammad M Mamdani; David N Juurlink; Tara Gomes Journal: JAMA Netw Open Date: 2021-10-01